Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Apr;43(4):1669-73.
doi: 10.1128/JCM.43.4.1669-1673.2005.

Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay

Affiliations
Clinical Trial

Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay

Karine Gourlain et al. J Clin Microbiol. 2005 Apr.

Abstract

Accurate quantification of hepatitis C virus (HCV) RNA is needed in clinical practice to decide whether to continue or stop pegylated interferon-alpha-ribavirin combination therapy at week 12 of treatment for patients with chronic hepatitis C. Currently the HCV RNA quantification assay most widely used worldwide is the Amplicor HCV Monitor v2.0 assay (Roche Molecular Systems, Pleasanton, Calif.). The HCV RNA extraction step can be automated in the Cobas Ampliprep device. In this work, we show that the dynamic range of HCV RNA quantification of the Cobas Ampliprep/Cobas Amplicor HCV Monitor v2.0 procedure is 600 to 200,000 HCV RNA IU/ml (2.8 to 5.3 log IU/ml), which does not cover the full range of HCV RNA levels in infected patients. Any sample containing more than 200,000 IU/ml (5.3 log IU/ml) must thus be retested after dilution for accurate quantification. These results emphasize the need for commercial HCV RNA quantification assays with a broader range of linear quantification, such as real-time PCR-based assays.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Relationship between the HCV RNA levels measured in the undiluted (neat) and diluted samples in the Cobas Amplicor HCV Monitor v2.0 assay after HCV RNA extraction in the Cobas Ampliprep device. All samples falling above 100,000 IU/ml (5.0 log IU/ml) were retested after 1/100 dilution. The regression line is shown as a solid line, in comparison with the main diagonal (dashed line).
FIG. 2.
FIG. 2.
Median value and distribution of the log HCV RNA level in the diluted sample minus the log HCV RNA level in the undiluted (neat) sample, according to the initial viral level in the undiluted sample.
FIG. 3.
FIG. 3.
Proportion of samples for which a difference of more than 0.3 log (twofold; gray-shaded columns) and more than 0.5 log (threefold; black-shaded columns) was found between the HCV RNA levels measured in the undiluted (neat) and the diluted sample, respectively, according to the initial viral level in the undiluted sample.

Similar articles

Cited by

References

    1. Consensus panel. 2002. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. Hepatology 36:S3-S20. - PubMed
    1. Enomoto, M., S. Nishiguchi, S. Shiomi, M. Tanaka, K. Fukuda, T. Ueda, A. Tamori, D. Habu, T. Takeda, Y. Yano, and S. Otani. 2001. Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. J. Gastroenterol. Hepatol. 16:904-909. - PubMed
    1. Lee, S. C., A. Antony, N. Lee, J. Leibow, J. Q. Yang, S. Soviero, K. Gutekunst, and M. Rosenstraus. 2000. Improved version 2.0 qualitative and quantitative Amplicor reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J. Clin. Microbiol. 38:4171-4179. - PMC - PubMed
    1. Martell, M., J. Gomez, J. I. Esteban, S. Sauleda, J. Quer, B. Cabot, R. Esteban, and J. Guardia. 1999. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J. Clin. Microbiol. 37:327-332. - PMC - PubMed
    1. Neumann, A. U., E. Hagai, S. W. Schalm, M. von Wagner, G. Germanidis, Y. Lurie, G. Missale, M. Martell, J. M. Vrolijk, C. Hezode, G. Norkrans, F. Negro, A. Soulier, E. Verheij-Hart, G. Colucci, C. Ferrari, S. Zeuzem, and J. M. Pawlotsky. 2003. Early viral kinetics prediction of sustained virological response after 1 or 4 weeks of peginterferon alfa-2a and ribavirin therapy (DITTO project). Hepatology 38:248A.

Publication types

MeSH terms

LinkOut - more resources